Analysis of *Plasmodium falciparum* Pfcr7 and Pfmdr1 genes in parasite isolates from asymptomatic individuals in Southeast Nigeria 11 years after withdrawal of chloroquine

Moses N. Ikegbunam1,6*, Charles N. Nkonganyi2, Bolaji N. Thomas3, Charles O. Esimone1,6, Thirumalaisamy P. Velavan2,4 and Olusola Ojurongbe5

**Abstract**

**Background:** A reversal of chloroquine (CQ) resistance following a period of withdrawal has raised the possibility of its re-introduction. This study evaluated the current prevalence of Pfcr7 and Pfmdr1 alleles in *Plasmodium falciparum* isolates, 11 years after CQ withdrawal in Southeast Nigeria.

**Methods:** Filter-paper blood samples were collected from 725 non-febrile individuals, comprising 250 children (≤ 12 years), 250 pregnant women and 225 other adults, between October 2014 and February 2015 in Nnewi town, Southeast Nigeria. Nested PCR followed by direct sequencing was employed for the genotyping of Pfcr7 and Pfmdr1 genes.

**Results:** A total of 103 parasites-positive samples were recovered, comprising of 48 (19.20%) among children, 20 (20.00%) among pregnant women and 35 (15.50%) among other adults cohort. The frequency of the mutant genotype of Pfcr7 76T, 75E and 74I was 94.50% each. Parasite isolates from children had a frequency of 100% for mutant alleles in all Pfcr7 codons while isolates from pregnant women and other adults had a frequency of 91% each in all codons. Haplotype distribution of pfcr7 gene were 5.45, 0.00 and 76.37% for CVMNK, SVMNT and CVIET, respectively. For Pfmdr1 gene, the frequency of 86Y, 184F and 1246Y mutant alleles were 8.54, 29.27 and 3.66%, respectively. Amongst the Pfmdr1 haplotypes analysed, NFD had the highest frequency of 24.4%, followed by YFD at 6.10%. NYF and NYY occurred the least (1.20%).

**Conclusion:** The high level of Pfcr7 mutations is suggestive of a sustained CQ pressure on *P. falciparum* isolates in the study area, despite the change of first line treatment from CQ to artemisinin combination therapy for 11 years. A new strategy to ensure the complete withdrawal of CQ from the country is recommended.

**Keywords:** *Plasmodium falciparum*, Drug resistance, Chloroquine, Pfmdr1, Pfcr7

*Correspondence: mn.ikegbunam@unizik.edu.ng
1 Department of Pharmaceutical Microbiology and Biotechnology, Nnamdi Azikiwe University, Awka, Nigeria
2 Full list of author information is available at the end of the article

© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Drug resistance in *Plasmodium falciparum* has led to a major setback in the control and eradication of malaria across the globe, including Nigeria [1, 2]. Chloroquine (CQ), a safe and cheap anti-malarial was once the drug of choice for treating uncomplicated falciparum malaria for several decades [3]. However, the emergence of CQ-resistant malaria parasites, first reported in Southeast Asia along the Thai-Cambodian border during the late 1950s, and now spread across the globe, has greatly hampered the usefulness of this drug [4]. In Nigeria, the first emergence of CQ-resistant malaria parasites was reported in the southern region in 1987 and later spread across the country [1, 5]. Following high level resistance of *P. falciparum* to CQ, Nigeria changed the first-line option for the treatment of malaria from CQ to artemisinin combination therapy (ACT), with artemether-lumefantrine (AL) in 2005 [1, 6]. Published reports have shown that the switch from CQ to ACT in areas where CQ-resistant *P. falciparum* is prevalent has resulted in the re-emergence of CQ-sensitive strains, a few years after the cessation of CQ use [7], although some other studies have reported otherwise [8, 9].

Surveillance of CQ-resistant *P. falciparum* has relied on molecular methods that have allowed for better understanding of the emergence and spread of drug resistance genes. *Plasmodium falciparum* CQ resistance transporter (*PfCRT*) gene, located on chromosome 7 with 13 exons encoding 424 amino acid transmembrane protein of 48.6 kDa molecular mass, was identified as CQ resistance marker [10]. It is believed that K76T mutation is the principal determinant of CQ resistance and susceptibility [10]. Other common mutations, C72S, M74I, N75E, A220S, Q271E, I356T, R371I, have also been shown to confer resistance in association with K76 mutation [10, 11]. In addition, point mutation in *P. falciparum* multidrug resistance protein 1 (*Pfmdr1*) gene located on chromosome 5, with one exon which codes for P-glycoprotein homologue 1 with 1419 amino acids and 162.25 kDa [12, 13] has been reported to modulate sensitivity and resistance to multiple anti-malarials. It is known that polymorphism, amplification and variation in mRNA expression level of *Pfmdr1* gene are responsible for resistance to various anti-malarials and sudden uptick of multidrug parasites [12]. Mutations at positions N86Y, Y184F, S1034, N1042D, and D1246Y of *Pfmdr1* have been shown to be responsible for either susceptibility or resistance to CQ, quinine, mefloquine, halofantrine, lumefantrine, and artemisinin [14–17].

The prevalence of asymptomatic malaria in Nigeria has been reported to range from 25% [18] to 59% [19, 20] in some regions of the country. Asymptomatic infection is an important obstacle in malaria control since such asymptomatic carriers do not seek treatment and thereby remain reservoirs for the life cycle of the infection to continue. The systematic identification and characterization of *P. falciparum* drug-resistant genes in asymptomatic individuals as part of surveillance intervention strategy is, therefore, very important for reducing the parasite reservoir and transmission of the disease. The current study investigated the prevalence of *PfCRT* and *Pfmdr1* alleles that have been recognized as CQ markers in *P. falciparum* isolates collected from asymptomatic individuals eleven years after withdrawal of CQ.

Methods

Study area, study population and ethics

The study was conducted in Nnewi town, Anambra State, Southeastern Nigeria, with a population of 194,002 people, annual rainfall of about 1.4 m, and lies mainly in the deciduous forest area, spreading towards the grassland belt (National Census, 2006). Malaria is present throughout the year, with a marked increase during the rainy season, which normally runs from April to September.

Filter-paper blood samples were collected from 725 individuals, comprising 250 children under 12 years old and 225 adults during a community survey. Additional 250 filter-paper blood samples were collected from pregnant women attending Nnewi district hospital. All the samples were collected between October 2014 and February 2015. All participants were without malaria symptoms, as defined inclusion criteria accommodated only participants without obvious symptoms of malaria (axillary temperature ≥37.5 °C or history of fever 72 h preceding presentation). Other enrolment criteria included absence of severe illness, a written consent from participants or guardians, and assent in cases where participants were children. Ethical approval for the study was obtained from the Ethics Review Board, University of Nigeria Teaching Hospital (approval number: NHREC/05/01/2008B-FWA00002458-IRB00002323).

Sample collection, processing and parasite detection

Blood was collected by finger prick and approximately 4 drops of blood were spotted on filter paper, air dried, individually sealed and stored at room temperature until DNA extraction. Genomic DNA was extracted from the dried blood spots using DNAeasy Blood & Tissue kit (QIAGEN, Hilden, Germany), according to the manufacturer’s instructions and kept at −20 °C until use. For the detection and identification of *P. falciparum*, the nested polymerase chain reaction (PCR) method described for all human malaria parasites molecular detection was used [21]. A first-step PCR was performed with specific primers rPLU1 and rPLU5 followed by genus specific (rFAL1/rFAL2—*P. falciparum*)-nested PCR. All PCR reactions
were performed in a 25 μl total volume, containing 1X buffer, 2.5 mM MgCl₂, 200 μM dNTPs, 200 nM primers, and 1U Taq DNA-polymerase (Qiagen, Hilden, Germany).

**Genotyping of Pfcrt and Pfmdr1 polymorphisms**

DNA was amplified using nested PCR in a 20 μl reaction volume containing 1 × buffer, 2.5 mM MgCl₂, 200 μM dNTPs, 2.0 mM Q-solutions (PCR additive), 200 nM primers, 1 U Taq Polymerase and 10 ng of DNA template on a PTC-200 Thermal cycler (MJ Research, USA). The primers, cycling parameters and the amplified codons are listed in Table 1. Amplified PCR products were prepared for sequencing using Exo-SAP-IT (USB, Affymetrix, USA) and directly used as templates for DNA sequencing with the BigDye terminator v. 1.1 cycle sequencing kit (Applied Biosystems, Foster City, USA) on an ABI 3130XL DNA sequencer. Single nucleotide polymorphisms (SNPs) were identified by assembling the sequences with each reference sequence utilizing Sequencher 4.7 software and were reconfirmed visually from their respective electropherograms.

**Results**

Total of 103 (n = 103) parasite-positive samples were recovered from children (n = 48), pregnant women (n = 20) and other adult cohort (n = 35). The general characteristics of the study population are presented in Table 2. For the children cohort, the mean age of the population was 3.17 ± 0.17 (age range 2 months to 10 years). Gender ratio was 159 male versus 92 females. The overall prevalence of *P. falciparum* in the children cohort was 19.20%. For pregnant women, the mean age was 31.10 ± 0.35 (age range: 19 to 59 years) and the prevalence of *P. falciparum* was 8%. In the other adult population, the mean age of the population was 36.83 ± 0.85 (age range: 13 years to 82 years, gender ratio: 0.98 [155:157]). The overall percentage prevalence of *P. falciparum* in this group was 15.60%.

**Frequency of the Pfmdr1 mutations**

Of the 103 parasite-positive samples, the *Pfmdr1* gene was successfully sequenced in 82 samples. The results for *Pfmdr1* polymorphisms are shown in Table 3. Twenty-one single nucleotide polymorphisms (SNPs) were observed

| Table 1 | Primer pairs used to amplify and sequence Pfcrt and Pfmdr1 |
|---------|------------------------------------------------------------|
| Gene    | Primer | Primer sequence                                               | PCR Cycling conditions                      |
| *P. falciparum* Genus | rPLU1   | TCAAGATTTAGCGCGGATGA                           | 25 cycles of 94 °C/1 min, 58 °C/1 min, and 72 °C/2 min |
| rPLU5   |         | CCGTGTGGTGGCTTTAAACTTC                          | 30 cycles of 94 °C/1 min, 58 °C/1 min, and 72 °C/2 min |
| rFAL1   |         | TTAACACTGTTTTGGGAAACCAATAATATT                  |                                              |
| rFAL2   |         | ACACAATGAACTCAATCTGACTGACCTGCCGTC              |                                              |
| Pfcrt SNPs | OF P1   | 5′-GACGAGGCTTAGAGAGATTA-3′                  | 35 cycles of 94 °C/30 s, 56 °C/30 s, and 62 °C/1 min |
| Codon   | OR P2   | 5′-CCAGTAGTTCTTGAAGACC-3′                     |                                              |
| 72 and 76| NF P3   | 5′-GGCTCCAGTTAGCTGGA-3′                       | 30 cycles of 94 °C/30 s, 56 °C/30 s, and 65 °C/1 min |
|         | NR P4   | 5′-GATATTTTCACTTTATATCT-3′                    |                                              |
| Pfmdr1 SNPs | OF P5   | 5′-AGCTGGAAGAAAGGTGAC-3′                      | 30 cycles of 94 °C/30 s, 55 °C/30 s, and 65 °C/1 min |
| Codon   | OR P6   | 5′-ATGACACCACAAACCAATAT-3′                    |                                              |
| 86 and 184| NF P7   | 5′-ACAAAAAGATCCGCTGAAT-3′                     | 30 cycles of 94 °C/30 s, 60 °C/30 s, and 65 °C/1 min |
|         | NR P8   | 5′-AACGCAAGATACATAATAC-3′                     |                                              |
|         | OF P9   | 5′-GTGTTTTTCTGAGAAG-3′                        | 34 cycles of 94 °C/30 s, 55 °C/60 s and 72 °C/1.5 min |
| Codon   | OR P10  | 5′-GACATTTAAATAACATGGGTTTC                   |                                              |
| 1034 & 1246| NF P11  | 5′-CAATGATGAAATGGTAAATGAGTC                  | 29 cycles of 94 °C/30 s, 60 °C/30 s, and 65 °C/1 min |
|         | NR P12  | 5′-TAAATAATGCGGTTCTTGACT                   |                                              |

| Table 2 | Demographic characteristics of the population |
|---------|---------------------------------------------|
| Characteristics of patients | Children cohort (n = 250) | Pregnant women cohort (250) | Other adult population (n = 225) |
| Mean age | 3.17 ± 0.17 | 31.10 ± 0.35 | 36.83 ± 0.85 |
| Age range (years) | < 1–12 | 19–59 | 19–82 |
| Gender ratio M:F | 159:92 | NA | 0.98 [155:157] |
| Number (%) positive for *P. falciparum* | 48 (19.20%) | 20 (8.00%) | 35 (15.60%) |
in the *Pfmdr1* gene, with the highest number among pregnant women (15), followed by children cohort (12). The highest frequency of point mutation was observed in the position Y184F (29.3%) with the children cohort recording the highest frequency (38.9%). The frequency of the N86Y mutation was 8.54%, with the children also recording the highest frequency (16.7%). The highest frequency of heterozygote (3.7%) was observed at position Y184F. All the mutations observed were as shown in the Table 3. At codon 1157, 1 (1.22%) sample had synonymous mutation. All the other mutations observed were non-synonymous.

### Table 3 Frequency and number of *Pfmdr1* mutations in the populations sampled at Nnewi, Southeast Nigeria

| Gene  | Children *(n = 36)* | Pregnant women *(n = 20)* | Other adults *(n = 26)* | Total *(n = 82)* |
|-------|---------------------|---------------------------|------------------------|-----------------|
|       | Mutants n (%)       | Mutants n (%)             | Mutants n (%)          | Mutant n (%)    | Heterozygote n (%) |
|       |                     |                           |                        |                 |                  |
| Pfmdr1| N86Y                | 6 (16.67)                 | 1 (5.00)               | 0 (0.00)        | 7 (8.54)         | 0 (0.00)          |
|       | Y158H               | 0 (0.00)                  | 1 (5.00)               | 0 (0.00)        | 1 (1.22)         | 0 (0.00)          |
|       | Y184F               | 14 (38.88)                | 4 (20.00)              | 6 (23.08)       | 24 (29.27)       | 3 (3.66)          |
|       | F74L                | 1 (2.77)                  | 0 (0.00)               | 0 (0.00)        | 1 (1.22)         | 0 (0.00)          |
|       | S164S               | 1 (2.77)                  | 0 (0.00)               | 0 (0.00)        | 1 (1.22)         | 0 (0.00)          |
|       | K1204E              | 0 (0.00)                  | 1 (5.00)               | 0 (0.00)        | 1 (1.22)         | 0 (0.00)          |
|       | Y1004H              | 0 (0.00)                  | 1 (5.00)               | 0 (0.00)        | 1 (1.22)         | 0 (0.00)          |
|       | S1066P              | 0 (0.00)                  | 0 (0.00)               | 0 (0.00)        | 0 (0.00)         | 1 (1.22)          |
|       | T1069T              | 1 (2.77)                  | 1 (0.00)               | 1 (3.85)        | 2 (2.44)         | 0 (0.00)          |
|       | A1077A              | 1 (2.77)                  | 2 (0.00)               | 0 (0.00)        | 1 (1.22)         | 0 (0.00)          |
|       | A1090A              | 0 (0.00)                  | 0 (0.00)               | 0 (0.00)        | 0 (0.00)         | 1 (1.22)          |
|       | N1106S              | 1 (2.77)                  | 0 (0.00)               | 0 (0.00)        | 1 (1.22)         | 0 (0.00)          |
|       | I1117V              | 1 (2.77)                  | 1 (0.00)               | 0 (0.00)        | 1 (1.22)         | 0 (0.00)          |
|       | R1176G              | 1 (2.77)                  | 2 (0.00)               | 0 (0.00)        | 1 (1.22)         | 0 (0.00)          |
|       | I1122T              | 1 (2.77)                  | 3 (0.00)               | 0 (0.00)        | 1 (1.22)         | 0 (0.00)          |
|       | K1129R              | 0 (0.00)                  | 1 (5.00)               | 0 (0.00)        | 1 (1.22)         | 0 (0.00)          |
|       | S1137S              | 1 (2.77)                  | 0 (0.00)               | 0 (0.00)        | 1 (1.22)         | 0 (0.00)          |
|       | D1246Y              | 2 (5.55)                  | 1 (5.00)               | 0 (0.00)        | 3 (3.66)         | 0 (0.00)          |
|       | G1114G              | 0 (0.00)                  | 0 (0.00)               | 0 (0.00)        | 0 (0.00)         | 1 (1.22)          |
|       | I1143V              | 0 (0.00)                  | 0 (0.00)               | 0 (0.00)        | 0 (0.00)         | 1 (1.22)          |
|       | T1157T              | 0 (0.00)                  | 1 (3.85)               | 1 (1.22)        | 0 (0.00)         | 0 (0.00)          |
|       | K1154K              | 0 (0.00)                  | 1 (5.00)               | 1 (1.22)        | 0 (0.00)         | 0 (0.00)          |
|       | T1224T              | 0 (0.00)                  | 1 (5.00)               | 0 (0.00)        | 1 (1.22)         | 0 (0.00)          |
|       | N1243K              | 0 (0.00)                  | 1 (5.00)               | 1 (1.22)        | 0 (0.00)         | 0 (0.00)          |
|       | R1244G              | 0 (0.00)                  | 1 (5.00)               | 0 (0.00)        | 1 (1.22)         | 0 (0.00)          |

**Haplotypes**

|       | NFD n (%)        | NFDn (%)      | YFDn (%) | NYDn (%) |
|-------|-----------------|--------------|----------|----------|
|       | 11 (30.56)      | 3 (15.00)    | 5 (13.89)| 1 (2.78) |
|       | 20 (24.39)      | 6 (23.08)    | 5 (6.10) | 1 (1.22) |

Frequency of the *Pfcr7* gene mutations with possible haplotypes

A total of 55 *P. falciparum* samples were successfully sequenced for the *Pfcr7* gene mutation with Table 4 showing the frequency of the mutations at different codons. All the samples had 100% wild type at codon 72. At codons 74, 75 and 76, the frequency of the mutation observed was 94.5% each, with the pregnant women recording 91% each followed by the adult group with 90.5% each. The resultant amino acid changes were all non-synonymous. For the haplotypes analysis, 52 (94.54%) had CVIET, 3 (5.45%) had CVMNK while none of the samples had SVMNT.
The frequency of *Pfcrt* and *Pfmdr1* combined mutations are shown in Table 5. Combined point mutations of the two most important positions 86Y/76T (8.70%) was observed only in parasites collected from children, while 184F/76T occurred across the three cohorts with frequencies of 39.10%, 27.30% and 23.80% for the children, pregnant women and other adults, respectively. None of the isolates had 1246Y/76T mutations. In total, 30.90% of the parasites analysed harboured 184F/76T combined mutation.

**Discussion**

This report provides insight into the *Pfcrt* and *Pfmdr1* genetic profile of *P. falciparum* isolates in asymptomatic individuals in Nnewi, Nigeria, and represent a unique place in the Southeast Nigeria on the prevalence of antimalarial resistance genes among asymptomatic individuals. Most of the isolates in this study had mutations on *Pfcrt* gene at codons 74I, 75E and 76T, while no mutation was detected at codon 72S. The overall prevalence of *Pfcrt* 76T was 94.56%, which is similar to the prevalence previously reported for isolates in other parts of the country [1, 22, 23]. The present high prevalence of the 76T in *Pfcrt* gene clearly demonstrated that CQ-sensitive strain of *P. falciparum* has not yet re-emerged, 11 years after changing the malaria treatment policy to ACT. This could be attributed to the sustained CQ pressure, possibly facilitated by the availability of CQ in most pharmacies in this location and in many parts of the country [6, 24]. There is also the possibility that there may be persistent circulation of the marker due to drug selection pressure from amodiaquine, and not necessarily from CQ [25]. The persistence of the mutant allele in the present study is in contrast to the report from other African countries such as Malawi [3, 26], Tanzania [27–30], Kenya [30, 31], Mozambique [32], and Ethiopia [7] following CQ withdrawal. In agreement with the current report however, isolates of *P. falciparum* from South America have been reported to harbour mutant alleles, despite the withdrawal of CQ [8]. There has been no study in Nigeria that suggests re-emergence of CQ-sensitive strains after CQ withdrawal, implying that this may require several more years for reversal to be observed or the need to revamp treatment policy in rural areas, or the availability of CQ in local pharmacies. Also, a very similar study conducted in Ethiopia showed continual circulation of *Pfcrt* 76T mutations after withdrawal of CQ for more than 12 years [33].

The present study also showed that the CVIET haplotype was predominant (94.54%) among other haplotypes of *Pfcrt* gene in the study area, which is consistent with other findings in Nigeria [22, 23]. In addition, CVMNK (wild type) haplotypes was detected in only 5.45% of the

### Table 4 Frequency and number of *Pfcrt* gene mutations with possible haplotypes in Nnewi, Southeast Nigeria

| Gene | Children n = 23 | Pregnant women n = 11 | Other adults n = 21 | Total n = 55 |
|------|----------------|-----------------------|---------------------|-------------|
| C72S | 0 (0.00)       | 0 (0.00)              | 0 (0.00)            | 0 (0.00)    |
| M74I | 23 (100)       | 10 (90.90)            | 19 (90.48)          | 52 (94.54)  |
| N75E | 23 (100)       | 10 (90.90)            | 19 (90.48)          | 52 (94.54)  |
| K76T | 23 (100)       | 10 (90.90)            | 19 (90.48)          | 52 (94.54)  |

### Table 5 Frequency of *Pfcrt* and *Pfmdr1* mutations in the three cohorts of asymptomatic individuals in Nnewi district, Southeast Nigeria

| Mutations   | Children n (%) | Pregnant women n (%) | Other adults n (%) | Total n (%) |
|-------------|----------------|----------------------|-------------------|-------------|
| 86Y/76T     | 2 (8.70)       | 0 (0.00)             | 0 (0.00)          | 2 (3.60)    |
| 184F/76T    | 9 (39.10)      | 3 (27.30)            | 5 (23.80)         | 17 (30.90)  |
| 1246Y/76T   | 0 (0.00)       | 0 (0.00)             | 0 (0.00)          | 0 (0.00)    |
| 86Y/184F/76T| 2 (8.70)       | 0 (0.00)             | 0 (0.00)          | 2 (3.60)    |
| 86Y/184F/1246Y| 0 (0.00)     | 0 (0.00)             | 0 (0.00)          | 0 (0.00)    |
| 86Y/184F/1246Y/76T| 0 (0.00) | 0 (0.00)             | 0 (0.00)          | 0 (0.00) |
isolates, mostly from pregnant women and other adult cohorts. Return of CQ-sensitive parasites (CVMNK haplotype) has been reported following cessation of CQ in some malaria-endemic countries, including Malawi [26], Gabon [34] and Brazil [35]. The absence of SVMNT haplotype observed in this study is in line with reports that confirm the absence of this haplotype in West Africa [36].

This study observed that the frequency of Pfdmrd1 gene mutations varied among the isolates from the three cohorts. Codon 184F (29.27%) mutation predominates all other mutations observed in the study area. Confirmed mutations observed had 8.54% and 3.66% for 86Y and 1246Y, respectively, and no mutation was detected for the 1042 and 1246 codon positions. Oladipo et al. observed a higher prevalence in 86Y (62.20%) and 184F (69.00%) in their findings for the Pfdmrd1 gene mutation among pregnant women in Lagos, Nigeria while no mutation was reported at codon 1246 [26]. Mutant Pfdmrd1 N86Y has been linked to amodiaquine pressure in The Gambia [12], Kenya [37] and Nigeria [25]. Thus, the present data could suggest that the parasites in the study area might be resistant to amodiaquine. Studies have also shown that increased copy number of Pfdmrd1 gene increases the risk of failure after treatment with mefloquine [38]. In Nigeria, some authors have reported high prevalence of 86Y allele of Pfdmrd1 in children with acute uncomplicated malaria in some other regions [39, 40].

The present study also reveals double (86Y/76T, 184F/76T) and triple (86Y/184F/76T) mutations in some of the isolates, particularly among children, potentially indicating that CQ exerts a selective pressure in this area. It could also reflect the extensive use of the drugs among children in the area, demonstrating that children are the major reservoirs for these combined resistance markers. Before now, double mutation at positions 184 and 1042 of Pfdmrd1 had been reported to reduce sensitivity to quinine, while mutations at positions 86 and 1042 increases the parasite’s susceptibility to quinine [41, 42]. If this present observation persists, the biggest challenge would be how to treat severe malaria among children, especially those with cerebral malaria, for which quinine is the medication of last resort.

**Conclusion**

This study reveals a high prevalence of Pfcrt mutant genotypes and haplotypes and low frequency of Pfdmrd1 mutant genotypes, 11 years after the switch in malaria treatment policy from CQ to ACT in Nnewi, Nigeria. This may suggest continual circulation and spread of CQ-resistant *Plasmodium falciparum* parasites in the study area. The continued use of unrecommended CQ for the treatment of malaria, and its possible availability in open market in Nigeria needs to be addressed urgently.

**Acknowledgements**

The authors are grateful to all parents/guardian and all individuals who volunteered to participate in the study. A special thanks to Albert Lallemruata and Christian Ngieute for sharing their expertise.

**Authors’ contributions**

MNI performed the field study and experiments, data analysis with drafting first draft; CNN, BNT, and COE contributed to the study design and study samples and revisions of manuscript; TPV supervised the experiments and revision of the manuscript; OI designed the experiments and revised the manuscript. All authors read and approved the final manuscript.

**Funding**

The study was supported by the Tertiary Education Trust Fund (TETFund) Benchmark Support Grant 2016/17 received by IMN.

**Availability of data and materials**

The datasets during and/or analysed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

A written consent from participants or guardians, and assent in cases where participants were children were obtained. Ethical approval for the study was granted by the Ethics Review Board, University of Nigeria Teaching Hospital, Enugu, South Eastern Nigeria (Approval number: NHREC/05/01/2008B-FWA00002458-IRB00002323).

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1 Department of Pharmaceutical Microbiology and Biotechnology, Nnamdi Azikiwe University, Awka, Nigeria. 2 Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany. 3 Department of Biomedical Sciences, College of Health Sciences and Technology, Rochester Institute of Technology, Rochester, NY, USA. 4 Faculty of Medicine, Duy Tan University, Da Nang, Vietnam. 5 Department of Medical Microbiology and Parasitology, Ladoke Akintola University of Technology, Osogbo, Osun State, Nigeria. 6 Molecular Research Foundation for Students and Scientists, Nnamdi Azikiwe University, Awka, Nigeria.

**Received: 12 February 2019 Accepted: 26 September 2019 Published online: 07 October 2019**

**References**

1. Ojurongbe O, Ogungbamigbe TO, Fagbenro-Beyioku AF, Fendel R, Krensmier PG, Kun JF. Rapid detection of Pfcrt and Pfdmrd1 mutations in *Plasmodium falciparum* isolates by FRET and in vivo response to chloroquine among children from Osogbo, Nigeria. Malar J. 2007;6:41.
2. Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, White NJ. Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. Am J Trop Med Hyg. 2003;187:179–86.
3. Kublin JG, Cortese JF, Njunju EM, Mukadam RAG, Wirima JI, Kazembe PN, et al. Reemergence of chloroquine-sensitive *Plasmodium falciparum* malaria after cessation of chloroquine use in Malawi. J Infect Dis. 2003;187:178–5.
4. Young MD, Contacos PG, Stickler JE, Willar JW. Drug resistance in *Plasmodium falciparum* from Thailand. Am J Trop Med Hyg. 1963;12:305–14.
5. Trape JF. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg. 2001;64:12–7.
25. Happi CT, Gbotosho GO, Aigbibi AO, Ogundahuni OA, Sovunumi A, Oduola AM. Potential contribution of prescription practices to the emergence and spread of chloroquine resistance in south-west Nigeria: caution in the use of artemisinin combination therapy. Malar J. 2009;8:313.

24. Meremikwu M, Okomo U, Nwachukwu C, Oyo-Ita A, Eke-Njoku J, Okebe Oladipo OO, Wellington OA, Sutherland CJ. Persistence of chloroquine-sensitive Plasmodium falciparum parasites and emergence of chloroquine-resistant Plasmodium vivax in Ethiopia. Malar J. 2014;13:244.

23. Adhin MR, Labadie-Bracho M, Brotas G. Molecular surveillance as monitoring tool for drug-resistant Plasmodium falciparum in Suriname. Am J Trop Med Hyg. 2013;89:311–6.

22. Olukosi YA, Oyebola MK, Alajaye OA, Okoko BA, Aina OQ, Agomo CO, et al. Persistence of markers of chloroquine resistance among Plasmodium falciparum isolates recovered from two Nigerian communities. Malar World J. 2014;3:2.

21. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, et al. Mutations in the Plasmodium falciparum digestive vacuole transmembrane protein PCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000;6:861–71.

20. Su X, Kirkman LA, Fujioka H, Wellems TE. Complex polymorphisms in an approximtely 330 kDa protein are linked to chloroquine-resistant Plasmodium falciparum in Southeast Asia and Africa. Cell. 1997;91:593–603.

19. Dutaisingh MT, Reuf P. Multiple drug resistance genes in malaria—from expression to epigenetics. Mol Microbiol. 2005;58:757–7.

18. Foote SJ, Thompson JK, Cowman AF. KEMP DJ. Amplification of the multidrug resistance gene and chloroquine resistance in some Plasmodium falciparum isolates. Cell. 1989;57:913–30.

17. Reed MB, Saliba KJ, Karuna SR, Kirk K, Cowman AF. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature. 2000;403:906–9.

16. Siow T, Stelzer S, Beeram S, Cowman AF. Pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol Microbiol. 2005;57:913–26.

15. Sisowath C, Stromberg J, Märtensson A, Mårtensson A, Msellem M, Obondo C, Björk J, et al. Antimalarial drug prescribing practice in private and public health facilities in South-east Nigeria: a descriptive study. Malar J. 2007;6:55.

14. Mekonnen SK, Aseffa A, Berhe N, Teklehaymanot T, Clauss RM, Gebru T, et al. Antimalarial drug resistance among children with asymptomatic malaria in apparently healthy schoolchildren in Ethiopia. J Vector Borne Dis. 2014;51:128–32.

13. Duraisingh MT, Refour P. Multiple drug resistance genes in malaria—from expression to epigenetics. Mol Microbiol. 2005;58:757–7.

12. Gama BE, de Oliveira NKA, Zalis MG, de Souza JM, Santos F, Daniel-Ribeiro IC, et al. Chloroquine and sulphadoxine-pyrimethamine sensitivity of Plasmodium falciparum parasites in a Brazilian endemic area. Malar J. 2009;8:156.

11. Tita T, Tanabe K, Kita K. Spread and evolution of Plasmodium falciparum drug resistance. Parasitol Int. 2009;58:201–9.

10. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, et al. Mutations in the Plasmodium falciparum digestive vacuole transmembrane protein PCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000;6:861–71.

9. Schwenke A, Brands C, Phillips J, Winkler S, Weisborders WH, Kremers PJ. Declining chloroquine resistance of Plasmodium falciparum in Lomé, Togo from 1992 to 1998. Wien Klin Wochenschr. 2001;113:63–4.

8. Gama BE, de Oliveira NKA, Zalis MG, de Souza JM, Santos F, Daniel-Ribeiro IC, et al. Chloroquine and sulphadoxine-pyrimethamine sensitivity of Plasmodium falciparum parasites in a Brazilian endemic area. Malar J. 2009;8:156.

7. Malmberg M, Ngasala B, Ferreira PE, Larsson E, Jövel I, Hjalmarsson A, Malmberg M, Ngasala B, Ferreira PE, Larsson E, Jövel I, Hjalmarsson A, et al. Persistence of markers of chloroquine resistance among Plasmodium falciparum isolates recovered from two Nigerian communities. Malar World J. 2014;3:2.

6. Meekonn TR, Aseffa A, Berhe N, Teklehaymanot T, Clauss RM, Gebru T, et al. Return of chloroquine-sensitive Plasmodium falciparum parasites and emergence of chloroquine-resistant Plasmodium vivax in Ethiopia. Malar J. 2014;13:244.

5. Adhin MR, Labadie-Bracho M, Brotas G. Molecular surveillance as monitoring tool for drug-resistant Plasmodium falciparum in Suriname. Am J Trop Med Hyg. 2013;89:311–6.

4. Gbotosho GO, Aigbibi AO, Ogundahuni OA, Sovunumi A, Oduola AM. Potential contribution of prescription practices to the emergence and spread of chloroquine resistance in south-west Nigeria: caution in the use of artemisinin combination therapy. Malar J. 2009;8:313.